Jane Street’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-11,200
Closed -$147K – 12627
2026
Q1
$147K Buy
+11,200
New +$168K ﹤0.01% 10401
2025
Q3
– Sell
-13,700
Closed -$153K – 11454
2025
Q2
$153K Buy
+13,700
New +$171K ﹤0.01% 8735

Other funds holding NPCE

Jane Street's NPCE Position: Q3 2026 in Review

Jane Street reduced its Neuropace (NPCE) stake by 59% in Q3 2026, selling an estimated $299K and leaving 14,271 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #10107.

Jane Street first reported a position in NPCE in Q2 2021 and has held it in 8 quarters since. The position peaked at $1.82M in Q4 2025. 105 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • Jane Street held 14,271 shares of Neuropace worth $196K as of Q3 2026.
  • Jane Street sold 20,167 Neuropace shares in Q3 2026, an estimated $299K.
  • Neuropace made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #10107 holding.
  • Jane Street first reported a position in Neuropace in Q2 2021 and has held it in 8 quarters since.
  • Jane Street's Neuropace position peaked at $1.82M in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.